US scientists come on board
You have no credits left. To view this article subscribe to Business News.
You have used {{points}} and have {{current_points}} remaining. Your credits will reset on {{reset_date}}.
This article is part of a special report and is available to paid Business News subscribers only.
You can purchase access to this special report or subscribe to Business News.
You can purchase access to this special report or subscribe to Business News.
This article is premium content and is available to paid Business News subscribers only.
Subscribe to Business News.
Subscribe to Business News.
Tuesday, 27 January, 2004 - 21:00
AUSTRALIAN Cancer Technology has appointed two US medical scientists to its scientific advisory board.
Rick Phipps and Professor Kerry O’Banion, both from the University of Rochester School of Medicine will join neuroscientist Professor David Felten and oncologist Professor Barry Body on the advisory board.
Professor Phipps, an immunologist and cancer researcher with interests in lung diseases and lymphomas is the director of the university’s lung biology and diseases program.
Professor O’Banion, associate professor of neurobiology and anatomy, is internationally known for his work on cyclooxgenase-2 and its critical role in neuroinflammation and neurodegenerative diseases. He is a co-holder of the patents for the use of COX-2 inhibitors.